Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Metformin Treatment for Diabetes Mellitus Correlates with Progression and Survival in Colorectal Carcinoma

MK. Powell, D. Cempirkova, P. Dundr, T. Grimmichova, F. Trebicky, R. E Brown, J. Gregorova, M. Litschmannova, K. Janurova, M. Pesta, P. Heneberg,

. 2020 ; 13 (2) : 383-392. [pub] 20191230

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005435

BACKGROUND: Diabetes mellitus is unfavorably associated with cancer risk. The purpose of this multidisciplinary project was to evaluate a possible association of diabetes mellitus and other comorbidities and their treatment with progression of colorectal cancer. PATIENTS AND METHODS: We investigated the correlation between pathological characteristics and clinical course, including comorbidities in 1004 Czech patients diagnosed and surgically treated for colorectal adenocarcinoma (CRC) between 1999 and 2016. RESULTS: In our data set, CRC patients treated with metformin due to coexisting diabetes mellitus type 2 (T2DM) developed fewer distant metastases which clinically correlates with slower CRC progression. Survival in metformin subgroup was longer, particularly in men with CRC. Osteoporosis may be a negative factor of survival in CRC patients. CONCLUSIONS: Our findings also indicate that aging, higher tumor grade and TNM stage, coexistence of selected endocrine disorders, and metabolic abnormalities may change the tumor microenvironment and impact survival in colorectal cancer, although mechanism of these observations yet to be explained. Patients with diabetes mellitus type 2 treated with metformin may represent the altered microenvironment with specifically tuned metabolic molecular responses and with various epigenetic characteristics. More awareness and increased understanding of the mechanisms underlying the positive effect of metformin on patients' survival could offer insight into new treatment methods and permit more individualized treatment plans.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005435
003      
CZ-PrNML
005      
20200528085129.0
007      
ta
008      
200511s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.tranon.2019.10.011 $2 doi
035    __
$a (PubMed)31896527
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Powell, Marta K $u Third Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Pathology, Hospital Jablonec Nad Nisou, Jablonec Nad Nisou, Czech Republic; Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Electronic address: mp1348@hotmail.com.
245    10
$a Metformin Treatment for Diabetes Mellitus Correlates with Progression and Survival in Colorectal Carcinoma / $c MK. Powell, D. Cempirkova, P. Dundr, T. Grimmichova, F. Trebicky, R. E Brown, J. Gregorova, M. Litschmannova, K. Janurova, M. Pesta, P. Heneberg,
520    9_
$a BACKGROUND: Diabetes mellitus is unfavorably associated with cancer risk. The purpose of this multidisciplinary project was to evaluate a possible association of diabetes mellitus and other comorbidities and their treatment with progression of colorectal cancer. PATIENTS AND METHODS: We investigated the correlation between pathological characteristics and clinical course, including comorbidities in 1004 Czech patients diagnosed and surgically treated for colorectal adenocarcinoma (CRC) between 1999 and 2016. RESULTS: In our data set, CRC patients treated with metformin due to coexisting diabetes mellitus type 2 (T2DM) developed fewer distant metastases which clinically correlates with slower CRC progression. Survival in metformin subgroup was longer, particularly in men with CRC. Osteoporosis may be a negative factor of survival in CRC patients. CONCLUSIONS: Our findings also indicate that aging, higher tumor grade and TNM stage, coexistence of selected endocrine disorders, and metabolic abnormalities may change the tumor microenvironment and impact survival in colorectal cancer, although mechanism of these observations yet to be explained. Patients with diabetes mellitus type 2 treated with metformin may represent the altered microenvironment with specifically tuned metabolic molecular responses and with various epigenetic characteristics. More awareness and increased understanding of the mechanisms underlying the positive effect of metformin on patients' survival could offer insight into new treatment methods and permit more individualized treatment plans.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cempirkova, Dana $u Department of Pathology, Hospital Jindrichuv Hradec, Jindrichuv Hradec, Czech Republic.
700    1_
$a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
700    1_
$a Grimmichova, Tereza $u Third Faculty of Medicine, Charles University, Prague, Czech Republic; Medicine Department, University Hospital Kralovske Vinohrady, Prague, Czech Republic; Institute of Endocrinology, Prague, Czech Republic.
700    1_
$a Trebicky, Ferdinand $u Radiation Oncology, Na Bulovce Hospital, Prague, Czech Republic.
700    1_
$a E Brown, Robert $u Morphoproteomic Laboratory, UT Health McGovern Medical School, Houston, Texas, USA.
700    1_
$a Gregorova, Jana $u Clinical Pharmacy Department, Na Bulovce Hospital, Prague, Czech Republic.
700    1_
$a Litschmannova, Martina $u Department of Applied Mathematics, Faculty of Electrical Engineering and Computer Science, VSB - Technical University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Janurova, Katerina $u IT4Innovations, VSB - Technical University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Pesta, Michal $u Charles University, Faculty of Mathematics and Physics, Department of Probability and Mathematical Statistics, Prague, Czech Republic.
700    1_
$a Heneberg, Petr $u Third Faculty of Medicine, Charles University, Prague, Czech Republic.
773    0_
$w MED00177205 $t Translational oncology $x 1936-5233 $g Roč. 13, č. 2 (2020), s. 383-392
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31896527 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200528085126 $b ABA008
999    __
$a ind $b bmc $g 1524365 $s 1095490
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 13 $c 2 $d 383-392 $e 20191230 $i 1936-5233 $m Translational oncology $n Transl Oncol $x MED00177205
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace